Scarica l'app Stockscreener
1.70
3.66%
0.06
Pre-mercato:
1.73
0.03
+1.76%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.64
Aprire:
$1.66
Volume 24 ore:
8.18M
Relative Volume:
0.85
Capitalizzazione di mercato:
$465.57M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-1.1333
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-8.11%
1M Prestazione:
-13.71%
6M Prestazione:
+2.41%
1 anno Prestazione:
-74.20%
Intervallo 1D:
$1.62
$1.73
Intervallo di 1 settimana:
$1.59
$2.01
Portata 52W:
$1.16
$7.50
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.70 | 465.57M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Cantor Fitzgerald Comments on PACB FY2025 Earnings - MarketBeat
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped - MSN
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics - MSN
RNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
Chromosome-level genome assembly of the pine wood nematode carrier Arhopalus unicolor - Nature.com
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now - MSN
PacBio announces preliminary Q4 revenue of $39.2M - MSN
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownShould You Sell? - MarketBeat
PacBio Stock May Gain Following the Collaborated Launch of GutID - MSN
PACB Stock Declines Despite Promising HiFi Sequencing Findings - Yahoo Finance
Don't Ignore The Insider Selling In Pacific Biosciences of California - Simply Wall St
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Bought by Barclays PLC - MarketBeat
PacBio reports drop in annual revenue, launches new products By Investing.com - Investing.com Canada
PacBio reports drop in annual revenue, launches new products - Investing.com India
PacBio's HiFi Sequencing Achieves 93% Success Rate in Breakthrough Rare Disease Study - StockTitan
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue - Quantisnow
Pacific Biosciences COO Mark Van Oene sells shares for $69,979 - Investing.com India
Whole genome sequencing, assembly and annotation of the Southern Ground Hornbill – Bucorvus leadbeateri - Nature.com
Pacific Biosciences COO Mark Van Oene sells shares for $69,979 By Investing.com - Investing.com Canada
Insider Selling: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells 34,405 Shares of Stock - MarketBeat
Pacbio and Intus Bio Collaborate for Launch of Gutid - Marketscreener.com
PacBio Launches GutID: Revolutionary At-Home Microbiome Test Using HiFi Sequencing - StockTitan
Pacific Biosciences of California (NASDAQ:PACB) Upgraded to Sell at StockNews.com - MarketBeat
PacBio delivers first Vega systems to Berry Genomics By Investing.com - Investing.com Nigeria
PacBio delivers first Vega systems to Berry Genomics - Investing.com
PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets - Quantisnow
Why the Market Dipped But Pacific Biosciences of California (PACB) Gained Today - MSN
PacBio Delivers First Vega DNA Sequencers to Berry Genomics in Major China Expansion - StockTitan
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 7.2%What's Next? - MarketBeat
Pacific Biosciences of California Sees Unusually Large Options Volume (NASDAQ:PACB) - MarketBeat
PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Barclays PLC Boosts Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Chromosome-level genome assembly of Triplophysa bombifrons using PacBio HiFi sequencing and Hi-C technologies - Nature.com
Why Is Pacific Biosciences of California, Inc. (PACB) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Target Price from Analysts - MarketBeat
State Street Corp Boosts Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Third Generation Sequencing Market Key Players Analysis - openPR
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
China Neurogenomics Market Research 2024-2031, Profiles of Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, MGI Tech, Agilent, Revvity, Qiagen, Pacific Biosciences, Danaher, Oxford NanoporeResearchAndMarkets.com - WICZ
Fmr LLC Has $694,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):